Infections and hypogammaglobulinemia in myasthenia gravis patients receiving low-dose rituximab: a real-world cohort study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Infections and Hypogammaglobulinemia Among Myasthenia Gravis Patients on Long-Term Low-Dose Rituximab: Findings from a Retrospective Cohort Analysis

  • By

  • Rongjing Guo

  • Yifan Zhang

  • Ting Gao

  • Zhe Ruan

  • Chao Sun

  • Sijia Hao

  • Yonglan Tang

  • Qingqing Wang

  • Xiaoxi Huang

  • Xiangqi Cao

  • Zhuyi Li

  • Danni Liu

  • Yu Liu

  • Ting Chang

  • August 28, 2026

Share

  • 1

    The study analyzed infection and hypogammaglobulinemia incidence in 186 myasthenia gravis patients on long-term low-dose rituximab.

  • 2

    Infections occurred in 15.59% of patients, with lower respiratory tract infections being the most common.

  • 3

    Hypogammaglobulinemia affected 27.42% of patients and was an independent predictor of infection risk.

  • 4

    Higher baseline prednisone doses were significantly associated with an increased risk of severe lower respiratory tract infections.

  • 5

    The median follow-up for patients was 2.41 years, with infection rates of 13.41 and 9.20 per 100 person-years at 1 and 2 years, respectively.

Original Source(s)

Infections and hypogammaglobulinemia in myasthenia gravis patients receiving low-dose rituximab: a real-world cohort study

  • by Rongjing Guo, Yifan Zhang, Ting Gao, Zhe Ruan, Chao Sun, Sijia Hao, Yonglan Tang, Qingqing Wang, Xiaoxi Huang, Xiangqi Cao, Zhuyi Li, Danni Liu, Yu Liu, Ting Chang

  • August 28, 2026

Related Content

FDA approves oral dermatomyositis therapy

Phase 3 findings show improvements in physical function and skin disease activity.

Medical Oddities: Could multilingualism keep you young?

From multilingual minds to pomegranate hearts, gastric mischief, and swishable tea, science stays delightfully odd.

Standardizing SANS in Spaceflight

NASA experts set out new diagnostic and management guidance for spaceflight-associated neuro-ocular syndrome

  • August 27, 2026

  • 4 min